Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
about
Clinical Development of the E75 Vaccine in Breast CancerPeptide-Based Treatment: A Promising Cancer TherapyThe Promise of Preventive Cancer VaccinesAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondCancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesThe innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.Precision medicine in breast cancer: reality or utopia?Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsRecent advances in the development of breast cancer vaccines.Trial Watch: Peptide-based anticancer vaccines.New Immunotherapy Strategies in Breast Cancer.Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model.Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.Breast cancer and immunology: biomarker and therapeutic developments.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.Adjuvant HER2/neu peptide cancer vaccines in breast cancer.Cancer Prevention: Lessons Learned and Future Directions.Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period.Current status and future prospects of peptide-based cancer vaccines.Immunotherapy for breast cancer: past, present, and future.Peptide-Based Cancer Vaccine Strategies and Clinical Results.The development and use of the E75 (HER2 369-377) peptide vaccine.Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.Progress in nonviral gene therapy for breast cancer and what comes next?Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.Further insight into AE37 peptide vaccination in prostate cancer.Immunotherapy for Breast Cancer: What Are We Missing?A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
P2860
Q26745440-2D703B24-3769-4E2F-81C3-4123F6945F82Q26777032-41DE8C4F-19CC-4276-903F-E7EEEA361720Q26783742-71607103-A452-41E9-A2E9-D874A0AFC01CQ26853619-36BAB845-A832-4B9B-9F56-2AB16820D335Q28077815-7A475AAF-0D2D-4CE0-8067-6E54C5187515Q28080472-1415A906-7847-4AB7-A156-106DC67EB3FEQ33660069-C192203E-3238-42A3-A76D-8BFE0402FBC5Q33688821-A275D01B-CF25-4E8C-8114-C236EFD22F0CQ33809114-FD2B4510-F59D-426A-B32E-F8F31727721FQ33833475-C5F8F8F8-925B-4CDB-9D22-D3A1FDE44544Q34379303-1D4394A0-781B-40DA-8AA5-89E05921809BQ34483345-50E7D068-C0ED-4AA0-83F8-A90242285F1FQ34549227-D658FEBF-1B1A-4412-A957-04A40E446C16Q35832185-01167F1E-75EB-4D0E-BF2A-254284C0EF69Q36269694-EADECC45-AB61-477F-BB26-FD1C4853AC39Q36316627-0C8B8A37-A839-4534-917D-8BF9DE9FF9E5Q36394506-97892F36-D8F6-425B-AD55-C8A078F5864BQ37041195-134F02D8-CA4F-46B4-B825-3DB1287CDB67Q37334492-6143E638-3639-47FA-B01E-16D16125F1B2Q37509479-4B7DE1D5-EFDA-4E46-B915-7FE26BEE1998Q37662391-D0A2F6C0-2D99-440D-9B76-DBFD9CFF3547Q37716642-D272756A-C1C2-468C-990E-0B51A69F2A5BQ38584383-9A1D3EE7-8454-4441-93A7-67DF6EF26D04Q38600417-9AA4746B-E6B8-40F7-930B-6DED80DC7F3DQ38619194-74EA62EA-A9E5-4379-BB8F-4E536DE9717AQ38633206-2264D1EA-9D81-489C-BC22-8BC6C6579961Q38652183-D90281BF-6B4F-42E8-8194-DC6C803E5065Q38681307-E0BA7C39-1E8B-4CF7-B0D6-7BA4C0A88617Q38780728-7BB10FA4-4497-4CF0-A8D3-B2756B237B92Q38787696-DEC6147B-2EA2-4409-AC98-234B20D7302DQ38807849-097345D5-AA90-4ADF-B6DC-22B4A3B3A2C1Q38885965-5795E08D-1FEF-47A2-8046-934562107CBFQ38896822-00060734-60E0-4CF7-AC9F-8503E635FD28Q39194052-3B45F92E-3479-404E-B1A3-87FC928FB728Q40068135-6FFA36D2-693F-44DC-8DB3-7EB7F89FDA05Q41936513-17272AAE-9C12-4910-9BD8-ED07A78CC3C4Q42353666-900DFCB5-3592-4FCB-88AE-2041CF5AB876Q44668850-23379A6E-A007-47B3-B1FB-C52034A8B5AEQ45073466-98914747-8D07-4103-B255-8CDBA9BCB3C4Q46243184-DDFAE770-66CF-441F-9E0A-41724D15ECFC
P2860
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Final report of the phase I/II ...... gh-risk breast cancer patients
@ast
Final report of the phase I/II ...... gh-risk breast cancer patients
@en
Final report of the phase I/II clinical trial of the E75
@nl
type
label
Final report of the phase I/II ...... gh-risk breast cancer patients
@ast
Final report of the phase I/II ...... gh-risk breast cancer patients
@en
Final report of the phase I/II clinical trial of the E75
@nl
prefLabel
Final report of the phase I/II ...... gh-risk breast cancer patients
@ast
Final report of the phase I/II ...... gh-risk breast cancer patients
@en
Final report of the phase I/II clinical trial of the E75
@nl
P2093
P2860
P921
P356
P1433
P1476
Final report of the phase I/II ...... gh-risk breast cancer patients
@en
P2093
D van Echo
E A Mittendorf
E Schneble
G E Peoples
G T Clifton
J P Holmes
P2860
P304
P356
10.1093/ANNONC/MDU211
P577
2014-06-06T00:00:00Z